Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED | N.MMED.WA | N.MMED.WR | N.MMED.WS

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Shorting

<< Previous

Bullboard Posts

Next >>

Comment by TeddyTenBagson Apr 27, 2021 10:48pm

185 Views

Post# 33080203

RE:Shorting

No one is shorting this pal. Why don't you share with the group where you found this information?

Reality is you're trying to pump this like it's going to get some sort of WSB bounce if you say it's being shorted. Sounds like you're a bag holder to me.

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects